Cy Stein

Cy Aaron Stein, M.D., Ph.D.

  • Professor, Department of Medical Oncology & Therapeutics Research

Cy Aaron Stein, M.D., Ph.D.

Especialidades clínicas
  • Medical Oncology
Áreas de especialidad
  • Urology and Urologic Oncology
Enfoque de la investigación
  • Prostate Cancer


1500 East Duarte Road, Duarte, CA, 91010

Obtener instrucciones

Teléfono :  626-256-4673


  • 1982, Albert Einstein College of Medicine (AECOM) Bronx, NY, Awarded M.D.
  • 1978, Stanford University, Stanford, CA, Ph.D., Organic Chemistry
  • 1974, Brown University, Providence, RI, B.A

Beca de investigación

  • 1985 - 1988, National Cancer Institute, Bethesda, Maryland


  • 1983 -1985, Internal medicine resident, The New York Hospital-Cornell Medical Center, New York, NY


  • 1982 -1983, Internal medicine intern, The New York Hospital-Cornell Medical Center, New York, NY
  • California Medical License
  • Maryland Medical License
  • New York State Medical License
  • 1986, Diplomate, American Board of Internal Medicine
  • 1987, Diplomate, American Board of Oncology

Liu, W., Bulgaru, A., Haigentz, M., Stein, C.A., Perez-Soler, R., and Mani, S.  The bcl- 2-family of protein ligands as cancer drugs:  The next generation of therapuetics.  Curr. Med. Chem.-Anti-Cancer Agents,  2003 (3), 217-223.

Nichols, G. and Stein, C.A. "Modulation of the activity of bcl-2 in Waldenstrom's Macroglobulinemia using antisense oligonucleotides" Semin. Oncol. 2003, (30) 297-299.

Wang, L., Prakash, R., Stein, C.A., Koehn, R., and Ruffner, D.  "Progress in the Delivery of Therapeutic Oligonucleotides: Organ/cellular Distribution and Targeted Delivery of Oligonucleotides In Vivo", Antisense and Nucleic Acid Drug Development, 2003 (13) 169-189.

Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds).  Therapeutic Oligonucleotides.  Ann. NY Acad Sci., 2003 (1002).; Stein, C.A., Dias, N., Benimetskaya, L, Jepsen, J., Lai, J., and Raffo, A. "LY900003 (Isis 3521) and G3139 (Genasense; Oblimersen)-Phosphorothioate Antisense Oligonucleotides With Pleotropic Mechanisms of Action." Nucleic Acid Therapeutics in Cancer, A. Gewirtz, ed., 2004, 171-191.

Stein, C.A., Mani, S., Benimetskaya, L. "Combinations of Chemotherapy with Antisense Approaches Against bcl-2", in Combination Cancer Therapy:  Modulators and Potentiators, G., Schwartz, ed., Humana Press, 2005, p. 207-228; Stein, C.A., Benimetskaya, L., and Mani, S. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 7th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2005, p. 2891-2898.

Stein, C.A. and Rossi, J. "A Critical Assessment of the Potential of Short Interfering RNA Therapeutics', Drug Discovery Today: Technologies, 2005,; (2) 27-31.

Cho-Chung, Y., Gewirtz, A., and Stein, C.A. (eds).  Therapeutic Oligonucleotides-Transcriptonal and Translational Strategies for Silencing Gene Expression.  Ann. NY Acad Sci., 2005 (1058)

Benimetskaya, L., Lai, J., Khvorova, A., Wu, S., Miller, P. and Stein, C.A.  "Induction of Apoptosis by G3139 in Melanoma Cells", Ann. NY Acad. Sci, 2005 (1058) 235-245.

Stein, C.A., Benimetskaya, L., and Mani, S.  "Antisense Strategies for Oncogene Inactivation", Semin. Oncol. 2005, (32) 563-572.

Kornblum, N., Ayyanar, K., Benimetskaya, L., Richardson, P., Iacobelli, M., and Stein, C.A. "Defibrotide, a Polydisperse Mixture of Single-Stranded Phosphodiester Oligonucleotides with Life-Saving Activity in Severe Hepatic Veno-Occlusive Disease: Clinical Outcomes and Potential Mechanisms of Action", Oligonucleotides, 2006 (16), 105-114.

Stein, C.A. "The Genasense 'Learning Curve'", Letter to the Editor, Nature Biotechnology, 2007 (25) 972-973.; Stein, C.A.  "Genasense: It Ain't Over Till the Fat Lady Sings", Editorial, Oligonucleotides, 2007 (17) 345-348.

Stein, C.A. Kornblum, N., Lai, J., and Benimetskaya, L. "Genasense (G3139): An antisense Bcl-2 oligodeoxyribonucleotide with substantial clinical activity and a complex mechanism of action".  In Therapeutic Oligonucleotides, J. Kurreck, ed., Biomolecular Science, Royal Society of Chemistry, 2008, p. 23-42.

Stein, C.A., Benimetskaya, L., Kornblum, N., and Mani, S. "Antisense Agents", in Principles and Practice of Oncology, 8th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2008.; Stein, C.A., and Colombini, M.  "Specific VDAC Inhibitors:  Phosphorothioate Oligonucleotides" J. Bioenerg. Biomemb., 2008, 40:157-162.

Stein, C.A., Hoehn, B., and Rossi, J.  "Oligonucleotide Therapeutics"  In Principles of Anticancer Drug Development, E. Garrett-Mayer, et al., eds. Springer Press, 2011, p. 565-587.

Stein, C.A., and Soifer, H. "Antisense Inhibition of Gene Expression", in Principles and Practice of Oncology, 9th Ed., V. DeVita, et al., eds., J.B. Lippincott, New York, 2011.

Soifer, H., Koch, T., Hansen, B., Hoeg, A., Oerum, H., and Stein, C.A. "Silencing of Gene Expression by Gymnotic Delivery of Antisense Oligonucleotides" in M. Kaufmann and C. Klinger, eds., Functional Genomics:  Methods and Protocols: Methods in Molecular Biology, 815:333-346 Springer Press, 2011.

Stein, C.A., and Goel, S.  "Therapeutic Oligonucleotides-The Road Not Taken", invited commentary in Clinical Cancer Research, 2011, 17:6369-6372.

Twardowski, P. and Stein, C.A. "Beyond the Abstract-Direct regulation of androgen receptor activity in prostate cancer cells by potent CYP17 inhibitors"., July 2, 2012

Hu, J., Hsu, J., Bergerot, P., Yuh, B., Stein, C.A., and Pal, S.  "Preoperative therapy for localized prostate cancer: A comprehensive overview", Maturitas, 2013, 74:3-9.

Pal, S., Stein, CA, Sartor, O. "Enzalutamide for the treatment of prostate cancer," Expert Opinion in Pharmacotherapy, 2013, (14), 679-685

Eroglu, Z., Stein, C.A., Pal, S.  "Targeting angiopoietin-2 signaling in cancer therapy, Expert Opinion in Investigational Drugs, 2013, (22), 813-825.

Ir al Inicio